Christine Morton, MD
Otolaryngology · la Jolla, CANPI 1851589410
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Optinose US, Inc. at 55.6% of the total. Reporting peaked in 2019 at $196 and has fallen 91.0% since, to $18 in 2024. That places this record below the midpoint for otolaryngology clinicians in CA, where the typical reported total is $903.
Across 18 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$183
- Misonix Inc$28
- Bayer$23
- Aytu Biopharma, Inc.$21
- Myriad Genetic Laboratories, Inc.$21
- Sanofi$20
- plus $33 from 2 others
What the payments were for
- Food & beverage$329100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 10 | $183 |
| Misonix Inc | 2 | $28 |
| Bayer | 1 | $23 |
| Aytu Biopharma, Inc. | 1 | $21 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| Sanofi | 1 | $20 |
| Merck | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$329 in reported general payments places this provider in the 35th percentile of 1,021 otolaryngology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 168 | $1,899 |
| Ipratropium Bromide | 67 | $1,869 |
| Azelastine Hcl | 21 | $1,076 |
| Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort | 11 | $624 |
| Nystatin | 19 | $327 |
| Mupirocin | 39 | $293 |
| Doxycycline Hyclate | 19 | $271 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $191 |
| Triamcinolone Acetonide | 16 | $118 |
| Prednisone | 13 | $51 |
| Amoxicillin | 13 | $20 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in la Jolla
- Christopher Bergeronla Jolla$63K
- Brian WeeksSan Diego$924K
- Randall OwRoseville$613K
- Amir MoradiVista$389K
- Keith BlackwellLos Angeles$349K
- Kalpna DurairajSun Valley$348K
- Todd MillerNewport Beach$259K
- Jeffrey SuhLos Angeles$223K
- Dennis TangLos Angeles$209K
- Jeffrey FeinfieldThousand Oaks$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.